Pembrolizumab for PML and Pembrolizumab-induced Vasculitis Overview
Pembrolizumab, a humanized monoclonal antibody targeting PD-1, shows promise in treating PML with varied patient responses. Additionally, it is associated with vasculitis, with cases resolving upon treatment adjustments. Explore the clinical outcomes and implications in this comprehensive overview.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
Pembrolizumab for PML and Pembrolizumab-induced vasculitis Jonah Zuflacht 10/14/2021
Pembrolizumab A humanized monoclonal antibody that binds to lymphocyte programmed cell death protein 1 (PD-1) receptors, enhancing immune surveillance against tumor cells
Five patients had clinical improvement or stabilization of PML accompanied by a reduction in the JC viral load in the CSF and an increase in in vitro CD4+ and CD8+ anti JC virus activity. In the other three patients, no meaningful change was observed in the viral load or in the magnitude of antiviral cellular immune response, and there was no clinical improvement.
Pembrolizumab and vasculitis There were 53 cases of vasculitis of which 20 were confirmed. The main reported type of vasculitis was large vessel vasculitis and vasculitis of the central and peripheral nervous system. All cases resolved with either holding the immune checkpoint inhibitors and/or administering glucocorticoids. There were 4 cases of PACNS.
